 |
|
|
| |
Three-Day, Dose-Ranging Study Of The HCV NS3 Protease Inhibitor GS-9451
|
| |
| |
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
E Lawitz1, J Hill2, T Marbury3, M Rodriguez-Torres4, M DeMicco5, J Quesada6, P Shaw7, S Gordon8, M Shelton9, D Coombs9,
J Zong9, A Bae9, K Wong9, H Mo9, E Mondou9, K Hirsch9, W Delaney9
1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, Deland, FL, 3Orlando Clinical Research Center, Orlando, FL,4Fundacion De Investigacion De Diego, Santurce, PR,
5Advanced Clinical Research Institute, Anaheim, CA, 6West Coast Clinical Trials, Cypress, CA, 7Charles River, Tacoma, WA, 8Henry Ford Health System, Detroit, MI, 9Gilead Sciences, Inc. Foster City, CA.
|
| |
|
|
|
|
|
